



**THERMOGENESIS TO PRESENT
AT THE UBS GLOBAL LIFE SCIENCE CONFERENCE**

RANCHO CORDOVA, California (September 22, 2005) – ThermoGenesis Corp. (Nasdaq: KOOL) announced today that Philip Coelho, Chairman and Chief Executive Officer, will participate in the UBS Global Life Science Conference on Wednesday, September 28, 2005 at 3:00 pm EDT. Mr. Coelho will present an overview of the company's business activities and product pipeline. The UBS Conference will be held at the Grand Hyatt Hotel in New York, NY.

A live audio webcast of this presentation will be available at www.thermogenesis.com and a replay will be available for approximately 30 days after the webcast.

About THERMOGENESIS CORP.

ThermoGenesis Corp. is a leader in enabling technologies for cell therapeutics. The Company's technology platforms lead the world in their ability to produce biological products from single units of blood.

- The **BioArchive® System**, an automated robotic cryogenic device, is used by major cord blood stem cell banks in 26 countries as a key enabling technology for cryopreserving and archiving stem cell units for transplant.
- The **AutoXpress™ System**, currently undergoing Alpha testing, is a semi-automated robotic device and companion sterile closed blood processing disposable, to harvest stem cells from cord blood.
- The **CryoSeal® FS System**, a semi-automated device and companion sterile blood processing disposable, is used to prepare hemostatic and adhesive surgical sealants from the patient's blood in about an hour. Enrollment in a 150 patient U.S. pivotal clinical trial has been completed and a PMA is being prepared.
- The **Thrombin Processing Device (TPD™)** is a sterile blood processing disposable that prepares activated thrombin from a small aliquot of patient blood, or blood plasma in 25 minutes. The TPD market launch is underway in Europe.

The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

More Information, Contact:
THERMOGENESIS CORP.
Philip Coelho: (916) 858-5100